Transnasal Esophagoscopy (TNE) Esophageal Cancer Screening

NCT ID: NCT05480891

Last Updated: 2025-05-25

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 3 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-04-05
• Study Completion Date: 2025-03-19

Brief Summary

This research study is being done for 2 reasons: 1) The investigators want to learn about the eating, smoking and drinking habits of adults, 18 years of age and older, in various Chicago communities, and 2) the investigators want to offer screening for participants whose smoking and drinking habits put them at risk for cancer.

Detailed Description

There are longstanding disparities in healthcare outcomes in the United States. These differences often correlate from the effects of structural racism and how this factor has shaped healthcare in our society.

Esophageal cancer presents as one of two distinct histological cell types, adenocarcinoma and squamous cell carcinoma (SCC). The majority of White patients presenting with esophageal cancer are diagnosed with adenocarcinoma while Black and non-caucasian patients are more commonly diagnosed with squamous cell carcinoma. The detection and treatment of these two types of esophageal cancers vary.

Trans-nasal esophagoscopy (TNE) is used primarily to assess chronic acid reflux as well as Barrett's esophagus, both symptoms being associated with adenocarcinoma. The use of TNE for disease screening offers the opportunity for early diagnosis and treatment of esophageal adenocarcinoma. Currently there is no parallel method of screening and diagnosis for patients with the potential for squamous cell carcinoma (SCC).

In an effort to decrease the disease identification, diagnosis, and treatment gap between these populations, this study will evaluate the use of TNE as a screening tool for African-Americans and non-caucasian patients with high risk factors associated with the development of esophageal SCC.

All adult patients 18 years of age and older will be asked to participate in a survey at one of the UI Health community health centers. The survey will include questions about smoking and alcohol consumption habits, which have been shown to be specific risk factors associated with esophageal SCC. Additional information, such as the use of mentholated cigarettes and fortified wines will be surveyed as such products are selectively marketed in African American communities and may increase the prevalence of SCC in these communities. Following review of the survey results from the health centers, all patients presenting with a dysphasia or difficulty swallowing, and patients who are 40 years of age and older and who have been determined to be high risk for SCC based on their survey results, will be offered the opportunity to have a TNE screening for esophageal cancer. Data gathered as a result of the study will be shared with participating communities and with medical health providers in an effort to improve patient knowledge and access to quality healthcare.

There are longstanding, historical, and current disparities in healthcare outcomes in the United States.[1-4] While we often classify these differences as racial, they are more likely to correlate with the effects of systemic racism that manifest as societal determinants of health. Segregation, whether legally sanctioned or de facto, molds the composition of neighborhoods and significantly influences access to quality healthcare.

Esophageal cancer incidence, stage at diagnosis, and mortality is one disease process that highlights these discrepancies. This year, an estimated 19,260 adults, most of whom are expected to be males, will be diagnosed with esophageal cancer. The two major types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. In the United States, esophageal cancer is more common in Caucasians than African Americans/non-Caucasians. In Caucasians the disease is frequently diagnosed as an adenocarcinoma, which implies the cancer arose from gland producing cells in the body. Squamous cell carcinoma, which originates from skin cells and mucosal linings in the body, is more common in the African American/non-Caucasian populations.

The five-year survival rate for esophageal cancer was reported to be five per cent four decades ago. Today the survival rate has improved to approximately twenty per cent. However, in 1970, the survival rate for White males was approximately four times that of Black/non-caucasian males, and in 2021, that ratio persists. Simply stated, Black and non-caucasian men are more likely to die from squamous cell cancer (SCCA) of the esophagus than any other demographic in the United States. The reason for the disparity in survival rates may be the result of a more proactive early screening process in the White population as symptoms arise. Adenocarcinoma, the more common form of esophageal cancer in the Caucasian population is frequently associated with Gastro-Esophageal Reflux Disease (GERD) or Barrett's esophagus. Early screenings and diagnosis of these two precursor causes of adenocarcinoma allows for early detection and treatment, thereby decreasing mortality. [8,9,19] Survival of esophageal cancer is associated with disease stage at diagnosis. Five-year survival is nearly 50% if the disease is diagnosed early and has not metastasized to lymph nodes or surrounding tissues or organs. Once the cancer has spread to lymph nodes, the average rate of survival is approximately 25%. If the cancer is not diagnosed until it has spread to other, more distant parts of the body, survival is estimated to be around 5%.

Trans-nasal esophagoscopy (TNE) is currently used primarily to assess chronic acid reflux as well as to screen for Barrett's esophagus. Clinicians have tended to employ this screening tool to look for changes that could lead to adenocarcinoma of the esophagus in response to symptoms. Caucasian males over age 50 are the primary target group for the current screening paradigm. Published reports and guidelines for the use of TNE as a screening tool for adenocarcinoma are readily available to the medical community. Patients, once diagnosed for GERD or Barrett's esophagus have annual visits with a gastroenterologist for sustained screening. Conversely, African-American/non-caucasian males who are considered at lower risk for Barrett's esophagus may not be referred for screening surveillance. The fact that African-American and non-caucasian males, particularly those with a history of alcohol and tobacco consumption, may be at increased risk for esophageal squamous cell carcinoma has not led to a specific screening protocol for this patient population. In fact, certain risks, such as mentholated cigarettes and fortified wines, which are selectively marketed in non-caucasian communities, may be a major factor in the increased prevalence and severity of SCC in these specific communities.

This study aims to evaluate the use of TNE as a screening tool for targeted populations with known risk factors for esophageal SCC. Specific symptoms are considered for the use of TNE for the diagnosis and treatment of esophageal adenocarcinoma, which is most prevalent in white males. This study aims to evaluate a more extensive use of TNE as a screening tool for at risk African American/non-Caucasian populations for the early diagnosis and treatment of esophageal squamous cell carcinoma.

Conditions

Esophageal Cancer

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: CROSS_SECTIONAL

Interventions

Transnasal Esophagoscopy (TNE)

While seated in an upright position a topical numbing medicine will be sprayed in your nose and the back of your throat.

A thin, flexible tube less than ¼ inch in diameter, will be placed in one of your nostrils and advanced to the back of your throat. When the tube reaches the back of the throat you will be asked to drink sips of water to help move the tube into and down the esophagus as it is advanced. The tip of the tube has a small light and camera built in that allows the doctor to see the structures of the mouth and esophagus as the tube is advanced. Once the tube is in the esophagus, the physician will examine your esophagus for any abnormal changes.

Once the visual inspection is complete the tube will be gently removed through your nose. The procedure will take approximately 10-15 minutes of time.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Male and female patients 18 years of age or older
• Patients being seen at one of the UI Health Centers for an ear, nose, or throat related concern.
• Patients who have a history of both smoking and drinking.
• Patients must be willing to complete a study survey.
• Patients must understand the purpose and procedures of the study and be willing to participate.
• Patients who speak English.
• All adult men and women who meet the study criteria will be asked to participate in the study without regard to race, gender or socioeconomic status.

Exclusion Criteria

• Male and Female patients under the age of 18.
• Patients who are not being seen at one of the UI Health Community Health
• Centers for an ear, nose or throat related concern.
• Patients who do not have a history of both drinking and smoking.
• Patients unwilling to complete the study survey.
• Women who are pregnant will be excluded from both Part 1 and Part 2 of the study.
• Patients unable to understand the purpose and procedures of the study and/or who are not willing to participate.
• Patients who do not speak English.

Excluded or Vulnerable Populations

• Minors will be excluded from the study because they are not at risk for the factors being studied in the research.
• Subjects who are not English speaking will be excluded due to the limited capacity of the primary investigators to obtain informed consent in this population.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cures Within Reach

OTHER

Sponsor Role: collaborator

University of Illinois at Chicago

OTHER

Sponsor Role: lead

Responsible Party

H Steven Sims

Francis L. Lederer Professor, Otolaryngology - Head and Neck Surgery Director, The Chicago Institute for Voice Care (CIVC)

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

H. Steven Sims, MD

Role: PRINCIPAL_INVESTIGATOR

University of Illinois Chicago

Locations

Mile Square Health Center-University of Illinois Hospital

Chicago, Illinois, United States

University of Illinois

Chicago, Illinois, United States

Countries

United States

Other Identifiers

2022-0115

Identifier Type: -

Identifier Source: org_study_id